EGFR and non-small cell lung carcinoma: These results suggest that Golgi-targeted drugs might provide a novel therapeutic option for treating EGFR-activated NSCLC cells, and especially for overcoming TKI resistance by multiple mechanisms, by downregulating the cell surface expression of both mutated EGFR and MET involved in the EGFR-bypassing alternative pathway.